Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial

Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazquez, Jose A., Pappas, Peter G., Boffard, Kenneth, Paruk, Fathima, Bien, Paul A., Tawadrous, Margaret, Ople, Eric, Wedel, Pamela, Oborska, Iwona, Hodges, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190264/
https://www.ncbi.nlm.nih.gov/pubmed/37022196
http://dx.doi.org/10.1128/aac.01419-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190264/
https://www.ncbi.nlm.nih.gov/pubmed/37022196
http://dx.doi.org/10.1128/aac.01419-22

Ejemplares similares